

Technology Advisory Interests Register

Topic: Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Richard Nicholas	TAC Committee Member	Non-financial professional	I have attended a discussion (unpaid) with a comparator company (Novartis) about a paper I produced with Novartis in 2020 about an unrelated condition multiple sclerosis.	15/01/2026	It was agreed that Richard's declaration would not prevent them from participating in discussions on this appraisal
James Fotheringham	TAC Committee Member	Personal	A close personal friend is employed by Biogen	08/01/2026	It was agreed that James's declaration would prevent them from participating in discussions on this appraisal
Dr Channa Hewamadduma	Expert	Direct – financial	Biogen <ul style="list-style-type: none"> Sept/Oct 2022 - Teaching faculty of an educational meeting/ conference sponsored by Biogen May 2023- Speaker honoraria- ABN March 2023 Teaching faculty of an educational meeting/ conference sponsored by Roche and Biogen 	05/02/2024 03/02/2026	It was agreed that Dr Hewamadduma's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • January/2024 - Adhoc advisory meeting - Biogen <p>Roche</p> <ul style="list-style-type: none"> • March 2023 Development of Risdiplam use Practical Guidance for clinicians' part I • March 2023 Educational/speaker at conference • April 2023 Advisory Board – reconnecting Disengaged SMA Adults to adult services • July 2022 Development of Risdiplam use Practical Guidance for clinicians' part II • October 2023 Interviewed by Sky News on SMA treatment access 	<p>25/01/2024 03/02/2026</p>	
		Indirect	<ul style="list-style-type: none"> • National Chief investigator in a Biogen associated clinical trial- in set up • Chairing a Delphi panel on expert evidence gathering in managing gastro complication in Risdiplam- Medical writer is funded via Roche, though roche has no influence on content. • Member of an evidence synthesis group on fertility 		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>related implications of risdiplam – author of a publication in ready to submit manuscript.</p> <ul style="list-style-type: none"> Adhoc advisory board support and trial data interpretation - Novartis: December 2025 		
Dr Mariachristina Scoto	Expert	Direct – financial	<ul style="list-style-type: none"> Involved as principal investigator in clinical trials from Roche and Biogen. Received consultancy honoraria for Scientific Advisory boards and teaching initiatives for Roche, Novartis and Biogen. Involved as principal investigator in a Biogen sponsored trial. 	<p>11/12/2025</p> <p>05/02/2024</p> <p>17/10/2025</p> <p>03/02/2026</p>	It was agreed that Dr Scoto’s declaration would not prevent them from providing expert advice to the committee
		Direct – non-financial	Co- principal investigator of the SMA REACH UK network, currently co-funded by Roche, Biogen and Novartis.	11/12/2025	
		Indirect	<ul style="list-style-type: none"> Involved as principal investigator in clinical trials from Roche and Biogen. 	05/02/2024	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> Co- principal investigator of the SMA REACH UK network, currently co-funded by Roche, Biogen and Novartis. 	03/02/2026	
Portia Thorman	Expert	Financial	SMA UK have received restricted funding for community projects. They have also completed patient prospective work for the companies involved with this appraisal	11/11/2025 03/02/2026	It was agreed that Portia's declaration would not prevent them from providing expert advice to the committee

DRAFT